NICE has recommended funding for Iluvien in the UK for non-infectious uveitis affecting the posterior segment (NIPU).
A NICE recommendation for funding signifies that the NHS will pay for Iluvien prescriptions for the treatment of NIPU as part of its offering.
Iluvien is also funded for the treatment of diabetic macular edema (DME) in the UK.
“We continue to execute on our plans to launch Iluvien’s new indication in Europe for non-infectious posterior uveitis, a significant and, we believe, poorly-served medical need,” said Rick Eiswirth, President and CEO of Alimera Sciences.
“The positive funding recommendation from NICE facilitates patient access in England and Wales for this second indication with funding from the NHS.”